- Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update
- Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference
- Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
- Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
- Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
- Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers
- Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024
- Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor
- Aprea Therapeutics to Present at DDR Inhibitors Summit 2024
More ▼
Key statistics
On Wednesday, Aprea Therapeutics Inc (APRE:NAQ) closed at 5.03, 80.94% above the 52 week low of 2.78 set on Jul 07, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.01 |
---|---|
High | 5.20 |
Low | 4.94 |
Bid | 4.94 |
Offer | 5.40 |
Previous close | 5.10 |
Average volume | 13.06k |
---|---|
Shares outstanding | 5.43m |
Free float | 4.44m |
P/E (TTM) | -- |
Market cap | 27.68m USD |
EPS (TTM) | -3.32 USD |
Data delayed at least 15 minutes, as of May 22 2024 20:56 BST.
More ▼